Trial Profile
A Randomized Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Vinorelbine (Primary) ; Anastrozole; Letrozole
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 29 Jan 2021 Status changed from active, no longer recruiting to discontinued.
- 24 Jul 2019 Planned End Date changed from 1 Feb 2024 to 1 Feb 2022.
- 24 Jul 2019 Planned primary completion date changed from 1 Feb 2019 to 24 Feb 2021.